1. Academic Validation
  2. A series of benzensulfonamide derivatives as new potent carbonic anhydrase IX and XII inhibitors

A series of benzensulfonamide derivatives as new potent carbonic anhydrase IX and XII inhibitors

  • Future Med Chem. 2025 Feb;17(3):271-285. doi: 10.1080/17568919.2025.2453420.
Susanna Nencetti 1 Doretta Cuffaro 1 Lidia Ciccone 1 Alessio Nocentini 2 Miriana Di Stefano 1 Giulio Poli 1 Marco Macchia 1 Tiziano Tuccinardi 1 Elisa Nuti 1 Claudiu T Supuran 2 Armando Rossello 1 3 Elisabetta Orlandini 3 4
Affiliations

Affiliations

  • 1 Department of Pharmacy, University of Pisa, Pisa, Italy.
  • 2 Department of Neurofarba, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Sesto Fiorentino, Italy.
  • 3 Research Center "E. Piaggio" Università di, Pisa, Italy.
  • 4 Department of Earth Sciences, University of Pisa, Pisa, Italy.
Abstract

Aim: Human carbonic anhydrases (hCAs) are involved in many physiological processes including respiration, pH control, ion transport, bone resorption, and gastric fluid secretion. Recently, CA IX and CA XII have been studied for their role in Cancer diseases, motivating the design of inhibitors of these isoforms.

Material and method: Here, we used the tail approach to design a new series of monoaryl (1a-i) and bicyclic (1j-n) benzensulfonamide derivatives CA IX and CA XII inhibitors. All synthesized compounds were investigated toward a panel of hCAs, and most of them exhibited potent CA inhibitory activity for CA II, CA IX and CA XII with Ki values. In silico studies were performed to investigate the binding mode between inhibitors and CA.

Results and conclusion: The best compound was 1i that showed a low nanomolar range of Ki value as CA Inhibitor (Ki = 9.4, 5.6 and 6.3 nM hCA II, IX and XII, respectively).

Keywords

Carbonic anhydrase IX, XII; Carbonic anhydrase inhibitors (CAIs); benzensulfonamide derivatives; enzyme inhibition; metalloenzymes.

Figures
Products